Results 21 to 30 of about 302,876 (262)

Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015

BMC Pharmacology and Toxicology, 2019
Background This active, open observational study aimed to investigate adverse drug reactions (ADRs) associated with six commonly used antiepileptic drugs (AEDs) in southern Chinese outpatients with epilepsy from 2003 to 2015. Methods The Wenzhou Epilepsy
Yanru Du, Jiahe Lin, Jingzan Shen, Siqi Ding, Mengqian Ye, Li Wang, Yi Wang, Xinshi Wang, Niange Xia, Rongyuan Zheng, Hong Chen, Huiqin Xu   +11 more
doaj   +1 more source

Prediction model of thrombocytopenia on patients using linezolid: a ranked-based covariate selection with multi-center data

Frontiers in Pharmacology
BackgroundThrombocytopenia is a common adverse reaction of linezolid, often leading to severe complications. It is challenging to externally validate directly apply developed in other countries.
Nhi H. Nguyen, Hieu Le, Hieu Le, An Q. Tang, Hang T. H. Nguyen, Ha N. Tran, Tuyen T. Nguyen, Thuc T. N. Bui, Anh T. L. Dang, Oanh T. Khuat, Hoa D. Vu, Nhung T. H. Trinh, Anh H. Nguyen, Anh H. Nguyen   +13 more
doaj   +1 more source

The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity

Allergology International
Background: The conventional in vitro lymphocyte transformation test (LTT) for diagnosing drug hypersensitivity reactions (DHRs) is limited by low sensitivity. To improve detection and assess T cell activation strength, we adapted this test to a cytokine-
Tim Peyer, Lester Thoo, Daniel Yerly, Oliver Hausmann, Lukas Joerg, Werner J. Pichler   +5 more
doaj   +1 more source

Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis

SAGE Open Medicine, 2021
Background: Occurrence of adverse drug reactions is a major global health problem mostly affecting older adults. Identifying the magnitude and predictors of adverse drug reactions is crucial to developing strategies to mitigate the burden of adverse drug
Tadele Mekuriya Yadesa, Freddy Eric Kitutu, Serawit Deyno, Patrick Engeu Ogwang, Robert Tamukong, Paul E Alele   +5 more
doaj   +1 more source

Ranking Adverse Drug Reactions With Crowdsourcing

Journal of Medical Internet Research, 2015
BackgroundThere is no publicly available resource that provides the relative severity of adverse drug reactions (ADRs). Such a resource would be useful for several applications, including assessment of the risks and benefits of drugs and improvement of ...
Gottlieb, Assaf, Hoehndorf, Robert, Dumontier, Michel, Altman, Russ B   +3 more
doaj   +1 more source

Pharmacovigilance of Severe Cutaneous Adverse Drug Reactions

Clinical Dermatology Review, 2022
Background: Severe cutaneous adverse drug reactions (SCARs) are idiosyncratic reactions comprising 2% of all drug-induced skin reactions. These include Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis, drug reaction with eosinophilia and ...
Kriteeka Saini, Amita Sutaria, Bela Shah
doaj   +1 more source

Age-Associated Risk of Liver-Related Adverse Drug Reactions

Frontiers in Medicine, 2022
ObjectiveAging population is generally considered more sensitive to adverse drug reactions (ADRs). Yet, big data-based quantitative evidence currently does not exist to support this concept.
Yan-zhong Han, Yan-zhong Han, Yu-ming Guo, Peng Xiong, Fei-lin Ge, Jing Jing, Ming Niu, Xu Zhao, Zhao-fang Bai, Hai-bo Song, Xiao-he Xiao, Jia-bo Wang, Jia-bo Wang   +12 more
doaj   +1 more source

Dermoscopic Aspects of Cutaneous Adverse Drug Reactions

Dermatology Practical & Conceptual, 2021
Background: Little is known about the dermoscopic evaluation of cutaneous adverse drug reactions (CADRs). Objectives: To evaluate the dermoscopic patterns of CADRs and identify those associated with severe cutaneous adverse reactions to drugs (SCARDs).
Gabriela Rossi, André da Silva Cartell, Renato Marchiori Bakos   +2 more
doaj   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Children and ADRs (Adverse Drug Reactions)

Italian Journal of Pediatrics, 2010
Many medicines are prescribed to the paediatric population on an unlicensed or 'off-label' basis because they have not been adequately tested and/or formulated and authorized for use in appropriate paediatric age groups.
Napoleone Ettore
doaj   +1 more source